BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
2 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Wu D, Yan W, Han M, Ning Q. The potential immune regulation benefit of CpAMs beyond HBV suppression. Lancet Gastroenterol Hepatol 2021;6:680-2. [PMID: 34391513 DOI: 10.1016/S2468-1253(21)00256-9] [Reference Citation Analysis]
4 Lee YH, Cha HM, Hwang JY, Park SY, Vishakantegowda AG, Imran A, Lee JY, Yi YS, Jun S, Kim GH, Kang HJ, Chung SJ, Kim M, Kim H, Han SB. Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. ACS Med Chem Lett 2021;12:242-8. [PMID: 33603970 DOI: 10.1021/acsmedchemlett.0c00606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]